An observational study in Mild to Moderate Atopic Dermatitis, sponsored by BGP Products Operations GmbH, a Viatris company. Active, not recruiting at 9 sites in 3 countries. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by BGP Products Operations GmbH, a Viatris company · Observational
Elidel® is indicated for the short-term treatment and long-term management of signs and symptoms of atopic dermatitis (AD) in infants (3 to 23 months), children (2 to 11 years), adolescents (12 to 17 years), and adults. However, little evidence is available in literature in South and East Asian population. Hence, this non interventional study (NIS) is designed to capture data about the actual use of Elidel® in South and East Asian patients from 3 months to 12 years with mild to moderate AD.
Once the clinical decision has been made to prescribe Elidel® to a patient according to the local Package Insert, the investigator will consider recruiting the patient into this NIS. The decision to prescribe Elidel® must be prior to and independent from the decision to include the patient into the NIS.
As per study design:
End of Study will be approximately 6 months after the inclusion depending on length of the Elidel® Treatment Period. Collection of data includes but not limited to patients' demographics, clinical history, clinical symptom and manifestation, comorbidities, reported adverse events and concomitant medications. The patients' questionnaires (IDQOL and CDLQI) will be utilized to collect data directly from enrolled patients and transferred into the CRF.
This is the only study on the registry with BGP Products Operations GmbH, a Viatris company as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Approximately 130 patients will be enrolled.
Patients must meet all of the following inclusion criteria to be eligible for enrolment into the study:
Malaysia: Patients > 2 years and \<12 years old. Hong Kong: Patients >3 months and \<12 years old. Thailand: Patients >3 months and \<12 years old. Taiwan: Patients >3 months and \<12 years old.
Exclusion Criteria:
Patient candidates must not be enrolled in the study if they meet any of the following criteria:
Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
Change in Scoring Atopic Dermatitis (SCORAD) index
* Scoring Atopic Dermatitis (SCORAD) Index change in the Atopic Dermatitis (AD) areas from inclusion to the end of Elidel® treatment period (V2) * SCORAD Index ranges from 0 to 103. Higher scores represent a severe disease. * Higher change in the SCORAD index from inclusion to the end of treatment suggest a better improvement in the disease status.
Time frame: 6 months
Treatment Duration
Treatment duration with Elidel®
Time frame: 6 months
Change in symptoms over time
* Change in symptoms (itching and sleep loss) during Elidel® treatment period based on the Visual Analogue Scale (VAS) in the Scoring Atopic Dermatitis (SCORAD) index. * VAS ranges from 0 to 10. Higher scores represent a severe disease. * Higher change in VAS from inclusion to the end of treatment suggest a better improvement in the disease status.
Time frame: 6 months
Number of days lost
Number of days lost from school and/or work for patients and/or caregivers, assessed at each visit.
Time frame: 6 months
Adverse events over time
Elidel® safety and tolerability (adverse drug reactions \[ADRs\] and special situations \[SpS\]) during the whole study period.
Time frame: 6 months
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.